[Des-phe-insulin-containing intermediary insulin compared with usual commercial preparations (author's transl)].
In 20 type I diabetics comparison were made between Optisulin -depot CS (25% dissolved porcine Des-Phe-insulin/insulin and 75% crystalline porcine insulin), an intermediary insulin without depot additives, and two depot-additive containing insulins (Depot Insulin Hoechst CS and insulin Leo Mixtard) during a period of hospitalization. Des-Phe-insulins are insulins in which phenylalanine has been split off from the B chain of insulin. Since mixtures of Des-Phe-insulins with crystalline insulins are stable, there is the possibility of manufacturing monospecies-intermediary insulins without depot additives. Continued surveillance of blood sugar during application of Optisulin depot CS showed good control of the diabetic metabolism when compared with the commercially available insulins. Optisulin depot CS in its action is comparable to the two commercially available depot insulins. Side effects and allergic skin changes did not occur. Thus Optisulin depot SC adds to the at present available range of Des-Phe-insulin-containing insulins.
D000328:Adult; D000368:Aged; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D005260:Female; D006801:Humans; D007328:Insulin / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010649:Phenylalanine; D013552:Swine
D001786:Blood Glucose; D007328:Insulin; D010649:Phenylalanine
Des-Phe-insulinhaltiges Intermediärinsulin im Vergleich mit handelsüblichen Präparaten.